Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS reforms

It’s time to get diabetes right

Patients should have access to the right treatment and care, at the right time, says the ABPI Pharmaceutical Diabetes Initiative 

- PMLiVE

Pricing pressures preventing UK access to MenB vaccine

GlaxoSmithKline’s Bexsero will need a dramatic price cut to gain NHS entry

UK flag

Pharmacists to help England’s GPs manage patients, medicines

Comes as doctor groups fear that primary care is struggling under increasing workloads

- PMLiVE

Quality in Care’s 2015 diabetes programme launches at Diabetes UK

Now open for entries to celebrate best practice in NHS diabetes care

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

- PMLiVE

Greater Manchester to control its share of the NHS budget

The north-west English region accounts for 5% of the country's health spending

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

- PMLiVE

England’s Cancer Drugs Fund: Fixing a broken system

Following the culling of 16 medicines from the Fund PME looks at how to improve market access for new oncology products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links